hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06293469, orgStudyIdInfo id: IRB00434587, briefTitle: Accelerated Flap Coverage in Severe Lower Extremity Trauma, acronym: FLAP ATTACK, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2029-05, completionDateStruct date: 2029-11, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Johns Hopkins University, class: OTHER, collaborators name: McMaster University, collaborators name: University of Maryland, Baltimore, collaborators name: Orthopaedic Trauma Association, collaborators name: Foundation of Orthopedic Trauma, descriptionModule briefSummary: The goal of this randomized controlled trial is to determine if accelerated flap coverage compared to standard flap coverage timing leads to improved infection-related complications in patients with open fractures and/or dislocations below the knee. Eligible patients will be randomized to receive either a flap within a goal of 72 hours of injury or standard of care flap timing for the institution. The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility)., conditionsModule conditions: Open Tibia Fracture, conditions: Open Dislocation of Ankle, conditions: Extremity Fracture Lower, conditions: Extremity Injuries Lower, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 356, type: ESTIMATED, armsInterventionsModule interventions name: Accelerated Flap Coverage Surgery, interventions name: Standard of Care Flap Timing, outcomesModule primaryOutcomes measure: Clinical status, secondaryOutcomes measure: Mortality, secondaryOutcomes measure: Amputation, secondaryOutcomes measure: Unplanned re-operation, secondaryOutcomes measure: Number of days in hospital, secondaryOutcomes measure: Quality of life as assessed by the Limb-Q, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06293456, orgStudyIdInfo id: 23-360, briefTitle: Study of Poetic Dignity Therapy for Sexual and Gender Minority Patients at End of Life, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-01-29, primaryCompletionDateStruct date: 2026-01, completionDateStruct date: 2026-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Memorial Sloan Kettering Cancer Center, class: OTHER, descriptionModule briefSummary: The purpose of this study is to find out if dignity therapy is practical and works well for sexual and gender (SGM) patients in hospice care. SGM includes, but is not limited to, people who identify as lesbian, gay, bisexual, transgender, and/or queer/questioning (LGBTQ+). Dignity therapy is a type of psychotherapy where the clinician asks the patient questions to allow the patient to express their individual life story and ultimately be able to create a legacy document of their experiences that can be shared with their loved ones., conditionsModule conditions: End of Life, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Dignity Therapy, outcomesModule primaryOutcomes measure: the number of patients who complete the intervention, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Memorial Sloan Kettering Cancer Center, city: New York, state: New York, zip: 10065, country: United States, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False
protocolSection identificationModule nctId: NCT06293443, orgStudyIdInfo id: IMU-OP-TT-01, briefTitle: Evaluation of Functionality of Amputees According to the Medicare Functional K Classification System, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-15, primaryCompletionDateStruct date: 2024-03-15, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Medipol University, class: OTHER, descriptionModule briefSummary: The aim of our study is; To evaluate the functionality of lower extremity unilateral amputees, to ensure that the results of the Medicare Functional K Classification System, which provides subjective data for the evaluator, become an objective evaluation method and to determine the functional levels of unilateral amputees; To create an objective data set by applying one-leg standing test, ten meter walking test, L test, figure-8 walking test, joint range of motion, amputee mobility estimator scale, houghton scale and joint position sense evaluation tests., conditionsModule conditions: Amputation, conditions: Amputation; Traumatic, Leg, Lower, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, maskingDescription: participants underwent functional testing at clinical centers, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Lower extremity unilateral amputee, outcomesModule primaryOutcomes measure: Amputee Mobility Scale, secondaryOutcomes measure: One Leg Standing Test, secondaryOutcomes measure: Houghton Scale, secondaryOutcomes measure: 8-Shape Walking Test, secondaryOutcomes measure: joint range of motion, secondaryOutcomes measure: proprioception, secondaryOutcomes measure: l test, secondaryOutcomes measure: 10 Meter Walking Test, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istanbul Medıpol University, status: RECRUITING, city: Istanbul, country: Turkey, contacts name: Medipol University, role: CONTACT, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06293430, orgStudyIdInfo id: P002, briefTitle: Registry on Luma Vision's VERAFEYE System (ENLIgHT), acronym: ENLIgHT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09-15, primaryCompletionDateStruct date: 2025-03-15, completionDateStruct date: 2025-03-15, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: LUMA Vision Ltd., class: INDUSTRY, descriptionModule briefSummary: The objective of the study is to compile real-world data on the use of the VERAFEYE System in standard of care atrial fibrillation (AF) ablation procedures and left atrial appendage closure (LAAC) procedures.Results from this study will be used to guide development of the VERAFEYE System., conditionsModule conditions: Atrial Fibrillation, conditions: Left Atrial Appendage Closure, conditions: Atrial Arrhythmia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: VERAFEYE System, outcomesModule primaryOutcomes measure: Clinical Success of procedure, primaryOutcomes measure: Procedural Complications, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06293417, orgStudyIdInfo id: HT-EF-01, briefTitle: To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM, acronym: ENSEMBLE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2027-02-01, completionDateStruct date: 2027-02-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Korea University Anam Hospital, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are:* major adverse cardiovascular events within 48 months of the trial duration* microvascular events within 48 months of the trial duration, conditionsModule conditions: T2DM (Type 2 Diabetes Mellitus), conditions: Dyslipidemias, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 3958, type: ESTIMATED, armsInterventionsModule interventions name: Statin and Ezefeno, interventions name: Statin doubling, outcomesModule primaryOutcomes measure: major adverse cardiovascular events and diabetic microvascular events for 48 months, secondaryOutcomes measure: proportion of patients achieving Non-HDL-C less than 100mg/dL, secondaryOutcomes measure: proportion of patients achieving LDL less than 70mg/dL, secondaryOutcomes measure: change in Non-HDL-C at 48month from baseline, secondaryOutcomes measure: change in LDL at 48month from baseline, secondaryOutcomes measure: change in HDL-C at 48month from baseline, secondaryOutcomes measure: change in TG at 48month from baseline, secondaryOutcomes measure: change in LDL-C/HDL-C ratio at 48month from baseline, secondaryOutcomes measure: change in TC/HDL-C ratio at 48month from baseline, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Korea University Anam Hospital, city: Seoul, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06293404, orgStudyIdInfo id: column flexion, secondaryIdInfos id: AnkaraCHBilkent, type: OTHER, domain: AnkaraCHBilkent, briefTitle: The Effect of Spinal Column Flexion on Unilaterality of Spinal Anesthesia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-04, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Ankara City Hospital Bilkent, class: OTHER, descriptionModule briefSummary: The effect of two different positions on spinal anesthesia in hip fracture surgery, conditionsModule conditions: Hip Fractures, conditions: Spinal Anesthesia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Bupivacain, outcomesModule primaryOutcomes measure: Hemodynamic change, primaryOutcomes measure: Hemodynamic change, primaryOutcomes measure: Hemodynamic change, primaryOutcomes measure: Hemodynamic change blockade to the dependent lower limb in flexed and extended spine position., primaryOutcomes measure: Hemodynamic change blockade to the dependent lower limb in flexed and extended spine position., primaryOutcomes measure: Hemodynamic change blockade to the dependent lower limb in flexed and extended spine position., secondaryOutcomes measure: To compare the efficacy, duration of motor block until return to normal function in the non-operated leg after the start of injection, of bupivacaine 7.5 mg/ml when used for spinal anaesthesia in patients undergoing unilateral lower, otherOutcomes measure: To compare the efficacy of bupivacaine 7.5 mg/ml in the duration of sensory block at dermatome T10 level, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06293391, orgStudyIdInfo id: 2022-11/2097, briefTitle: The Effect of Patient Position Changes on Advanced Cardiac Indices in Cancer Surgery, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-01, primaryCompletionDateStruct date: 2023-03-01, completionDateStruct date: 2024-02-05, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, class: OTHER, descriptionModule briefSummary: Esophageal Doppler Monitoring (Deltex CardioQ Esophageal Doppler Monitor, ODM) is used to manage patients' fluid therapy by non-invasively measuring continuous cardiac output with an esophageal probe. The aim of this study was to compare the effects of patient position changes on cardiac indices and vital signs in patients who underwent major abdominal cancer surgery with laparoscopic and open surgery using ODM., conditionsModule conditions: Abdominal Cancer, conditions: Blood Pressure, conditions: Cardiac Indices, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: cardiac indices in supine and trendelenburg position, outcomesModule primaryOutcomes measure: Cardiac Output, primaryOutcomes measure: Stroke Volume, primaryOutcomes measure: Flow time corrected, primaryOutcomes measure: Peak Velocity, primaryOutcomes measure: Stroke Distance, primaryOutcomes measure: Mean arterial pressure, primaryOutcomes measure: Pulse, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dr.Abdurrahman Yurtaslan Ankara Oncology Train and Research Hospital, city: Ankara, zip: 06200, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06293378, orgStudyIdInfo id: Pengmingli, briefTitle: Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2028-10-10, completionDateStruct date: 2028-11-10, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: The Second Affiliated Hospital of Chongqing Medical University, class: OTHER, descriptionModule briefSummary: This is a controlled, observational clinical study initiated by investigators to investigate the efficacy and safety of sulfasalazine in the treatment of cirrhosis in patients with cirrhosis. Four cohorts were planned: primary biliary cirrhosis, hepatitis B and C cirrhosis, and alcoholic cirrhosis. The four groups were divided into experimental group and control group, and the experimental group: each group of patients was orally treated sulfasalazine for 12 months, taken three times a day, each time taking 0.5g. The control group did not take sulfasalazine. After 12 months, changes in fecal flora and metabolites before and after the use of sulfasalazine were observed., conditionsModule conditions: Cirrhosis, Liver, conditions: Fibrosis, Liver, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 330, type: ESTIMATED, armsInterventionsModule interventions name: Sulfasalazine enteric-coated tablets, outcomesModule primaryOutcomes measure: Serum alkaline phosphatase (ALP), primaryOutcomes measure: Serum γ-glutamyl transpeptidase (GGT), primaryOutcomes measure: Serum bilirubin, primaryOutcomes measure: Serum bile acids, primaryOutcomes measure: Serum aspartate aminotransferase(AST), primaryOutcomes measure: Serum alanine aminotransferase (ALT), secondaryOutcomes measure: Hepatic fibrosis and the improvement of microbial metabolites, otherOutcomes measure: Changes in immune cells, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chongqing Medical University, status: RECRUITING, city: Chongqing, state: Chongqing, zip: 400000, country: China, contacts name: Mingli Peng, Doctor, role: CONTACT, phone: +8613512362906, email: Peng_mingli@hospital.cqmu.edu.cn, contacts name: Yinghua Lan, Doctor, role: CONTACT, phone: +8613796050629, geoPoint lat: 29.56278, lon: 106.55278, locations facility: Chongqing, status: RECRUITING, city: Chongqing, state: Chongqing, zip: 400000, country: China, contacts name: Mingli Peng, Doctor, role: CONTACT, phone: 13512362906, email: peng_mingli@hospital.cqmu.edu.cn, contacts name: Yinghua Lan, Doctor, role: CONTACT, phone: +8613796050629, geoPoint lat: 29.56278, lon: 106.55278, hasResults: False
protocolSection identificationModule nctId: NCT06293339, orgStudyIdInfo id: CoGA-Re, briefTitle: Durability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2024-11-01, completionDateStruct date: 2025-05-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Leiden University Medical Center, class: OTHER, descriptionModule briefSummary: This study will assess the durability of protection of a single immunisation with the Genetically Attenuated Parasite 2 (GA2) against controlled human malaria infection by rechallenging previously immunised and protected participants from the CoGA study (NCT05468606), conditionsModule conditions: Malaria,Falciparum, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 14, type: ESTIMATED, armsInterventionsModule interventions name: CHMI with 3D7 malaria, outcomesModule primaryOutcomes measure: Protective efficacy, primaryOutcomes measure: Time to parasitaemia, secondaryOutcomes measure: Humoral immune responses after homologous CHMI rechallenge, secondaryOutcomes measure: Cellular immune responses after homologous CHMI rechallenge, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06293300, orgStudyIdInfo id: 20231056, secondaryIdInfos id: HT94252310608, type: OTHER_GRANT, domain: Department of Defense Awarding Office: U.S. Army Medical Research Acquisition Activity (USAMRAA), briefTitle: Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-01, primaryCompletionDateStruct date: 2026-08-30, completionDateStruct date: 2026-08-30, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: University of Miami, class: OTHER, collaborators name: United States Department of Defense, descriptionModule briefSummary: The purpose of this research is to understand and treat Traumatic Brain Injury (TBI) associated photophobia (light sensitivity) and its impact on visual function., conditionsModule conditions: Traumatic Brain Injury, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: BoNT A, outcomesModule primaryOutcomes measure: Change in photophobia measured by Numerical Rating Scale, primaryOutcomes measure: Change in visual photosensitivity thresholds (VPT) measured Ocular Photosensitivity Analyzer (OPA), secondaryOutcomes measure: Change in severity of visual photosensitivity symptoms measured by Visual Light Sensitivity Questionnaire-8 (VLSQ-8), secondaryOutcomes measure: Change in severity of neuropathic ocular pain symptoms measured by Neuropathic Pain Symptom Inventory Questionnaire, modified for the Eye (NPSI-Eye)., secondaryOutcomes measure: Change in visual function related to activities of daily living measured by Visual Function Questionnaire-25 (VFQ-25), secondaryOutcomes measure: Change in migraine symptom severity score measured by in Migraine Symptom Severity Score (MSSS), secondaryOutcomes measure: Change in impact of headaches on daily life measured by Headache Impact Test (HIT)-6, secondaryOutcomes measure: Change in dry eye symptoms measured by the Dry Eye Questionnaire 5 (DEQ 5), secondaryOutcomes measure: Change in ocular surface disease index measured by the Ocular Surface Disease Index (OSDI), secondaryOutcomes measure: Change in pain intensity rating of aftersensations (AS) to repeated heat stimulation on the forehead measure by quantitative sensory testing (QST), secondaryOutcomes measure: Change in temporal summation (TS) of heat pain on the forehead measure by quantitative sensory testing (QST), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Miami, city: Miami, state: Florida, zip: 33136, country: United States, contacts name: Mariela Aguilar, PhD, role: CONTACT, phone: 305-326-6069, email: maguilar1@miami.edu, contacts name: Anat Galor, MD/MSPH, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 25.77427, lon: -80.19366, hasResults: False
protocolSection identificationModule nctId: NCT06293287, orgStudyIdInfo id: DJ-2023-02, briefTitle: Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-31, primaryCompletionDateStruct date: 2024-11-30, completionDateStruct date: 2025-01-30, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Zhongshan Hospital (Xiamen), Fudan University, class: OTHER, descriptionModule briefSummary: The present investigation is designed as a single-blind, randomized, controlled, bicentric trial. The objective is to ascertain whether the subcutaneous administration of enoxaparin sodium for prophylactic anticoagulation during transradial hepatic arterial infusion chemotherapy (HAIC) can diminish the incidence of radial artery occlusion (RAO) post-procedure, conditionsModule conditions: Radial Artery Occlusion, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 156, type: ESTIMATED, armsInterventionsModule interventions name: Subcutaneous enoxaparin sodium, interventions name: Placebo, outcomesModule primaryOutcomes measure: RAO rate after 24 hours and 21days, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 69 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhongshan Hospital, Fudan University (Xiamen Branch), status: RECRUITING, city: Xiamen, state: Fujian, zip: 361015, country: China, contacts name: BoHeng Zhang, PHD, role: CONTACT, phone: 0592-3501990, email: zhang.boheng@zs-hospital.sh.cn, geoPoint lat: 24.47979, lon: 118.08187, hasResults: False